Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Draxxin - withdrawal of application for variation to marketing authorisation

Draxxin - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn.

tulathromycin
Post-authorisationVeterinary

Page contents

  • Overview
  • Key facts
  • Related information on withdrawals
  • News on Draxxin
  • More information on Draxxin

Overview

On 17 January 2007 Pfizer Ltd officially notified the Committee for Medicinal Products for Veterinary Use (CVMP) that it wishes to withdraw its application for a new indication for the treatment of bovine interdigital necrobacillosis associated with Bacteroides melaninogenicus, Bacteroides nodosus and Fusobacterium necrophorum.

Questions and answers on the withdrawal of the application to change the marketing authorisation application for Draxxin

Reference Number: EMEA/CVMP/58270/2007

English (EN) (80.95 KB - PDF)

First published: 20/02/2007Last updated: 20/02/2007
View

Key facts

Name of medicine
Draxxin
EMA product number
EMEA/V/C/000077
Active substance
tulathromycin
International non-proprietary name (INN) or common name
tulathromycin
Species
  • Pigs
  • Cattle
  • Sheep
Anatomical therapeutic chemical veterinary (ATCvet) code
QJ01FA94
Marketing authorisation holder
Zoetis Belgium SA
Date of issue of marketing authorisation valid throughout the European Union
11/11/2003
Date of withdrawal
17/01/2007

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CVMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CVMP's evaluation is completed ('day 90').

News on Draxxin

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 13-14 February 2024
16/02/2024
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 10-12 May 2021
17/05/2021
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 18-20 May 2020
25/05/2020
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 21-22 May 2019
24/05/2019
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 April 2017
18/04/2017
Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 6-8 September 2016
09/09/2016
Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 17-19 May 2016
20/05/2016
Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 16-18 February 2016
19/02/2016
Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 10-12 March 2015
13/03/2015
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 8-10 July 2014
11/07/2014
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 6-8 May 2014
12/05/2014
Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 13-15 April 2010
16/04/2010
Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 9-11 February 2010
12/02/2010

More information on Draxxin

  • Draxxin
This page was last updated on 17/01/2007

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union